Switching From Originator Biological Agents to Biosimilars: What Is the Evidence and What Are the Issues?

RMD Open - United Kingdom
doi 10.1136/rmdopen-2017-000492
Full Text
Abstract

Available in full text

Date
Authors
Publisher

BMJ

Related search

What Is the Level of Evidence of What You Are Reading?

Dental Press Journal of Orthodontics
Oral SurgeryOrthodontics
2015English

The 'Scottish Approach' to Policy and Policymaking: What Issues Are Territorial and What Are Universal?

Policy and Politics
SociologyMonitoringPublic AdministrationManagementPolitical SciencePolicyLaw
2016English

Improving Instructional Pedagogy: What Are the Issues?

Education, Society and Human Studies
2020English

Biosimilars: What Do Patients Need to Consider?

RMD Open
RheumatologyAllergyImmunology
2015English

What Is the Best Evidence to Use in Practice?

American Journal of Occupational Therapy
MedicineOccupational Therapy
2000English

Editorial: Antigenic Response to CT-P13 and Infliximab Originator in IBD Shows Similar Epitope Recognition-Evidence From Basic Science Supports Safe Switching to Biosimilars. Authors’ Reply

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2018English

Biological Information — What Is It?

2013English

The Capable ABL: What Is Its Biological Function?

Molecular and Cellular Biology
Cell BiologyMolecular Biology
2014English

International Regulation and Treatment of Trade Finance: What Are the Issues?

SSRN Electronic Journal
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy